TAVR vs SAVR in Los Risk Patients: 10-Year Outcomes of the NOTION Trial

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of patients with severe aortic stenosis (AS). Randomized studies have shown the benefits of TAVR in patients at prohibitive surgical risk, as well as high and intermediate risk. 

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

The NOTION trial (Nordic Aortic Valve Intervention Trial) randomized patients with low risk severe AS to TAVR and surgical aortic valve replacement (SAVR). Outcomes showed no significant differences in mortality, stroke, acute MI 8 years after the intervention. 

Two other studies on low risk patients, the PARTNER 3 and EVOLUTE Low Risk, with 5 and 4 year follow-ups respectively, also found no significant differences between TAVR and SAVR in terms of all-cause mortality and disabling stroke. 

The aim of this multicenter randomized study was to look at clinical and prosthesis outcomes at 10 years. 

Primary end point was a combination of all cause death, stroke or AMI. Other clinical variables included transient ischemic attack, (TIA), atrial fibrillation (FA) de novo, new pacemaker implantation and endocarditis. Bio prosthesis durability was classified as bio prosthetic valve failure (BVF), defined as valve related death, severe structural hemodynamic deterioration or reintervention, and bio prosthetic valve dysfunction (BVD), classified as structural valve deterioration (SVD), non-structural valve dysfunction (NSVD), clinical valve thrombosis or endocarditis.

Read also: Third Generation Balloon-Expandable and Self-Expanding Valves: TAVR Meta- Analysis.

280 patients were enrolled, 145 were randomized to TAVR and 135 to SAVR. Mean age was 79.1 ± 4.8 years and 47% were women. Mean STS score was 3.0 ± 1.7%. After 10 years, the risk of primary end point was 65.5% for both groups (HR 1.0; CI 95% 0.7-1.3; p=0.9), with no significant differences in individual components of primary end point. 

Severe SVD (mean trans prosthetic gradient ≥30 mmHg, or ≥ 20 mmHg increase in 3 months, or new severe prosthesis leak) occurred in 1.5% of TAVR patients and 10% of SAVR patients (HR 0.2; CI 95% 0.04-0.7; P=0.02). Accumulated incidence of severe NSVD was 20.5% and 43.0% (P < .001), while endocarditis was 7.2% and 7.4% (P=1.0) after TAVR and SAVR, respectively. 

There were no valve thrombosis events. BVF occurred in 9.7% of TAVR patients vs. 13.8% of SAVR patients (HR 0.7; IC 95% 0.4-1.5; P=0.4). Patients in the SAVR group presented a higher rate of de novo AF (p<0.01), while TAVR patients presented higher need for pacemaker implantation (p<0.01).

Conclusion

After 10 years, the NOTION trial showed no significant differences between TAVR and SAVR in primary end point. Severe SVD risk was lower after TAVR vs SAVR, while BVF resulted similar between the groups. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial.

Reference: Hans Gustav Hørsted Thyregod et al European Heart Journal (2024) 00, 1–9.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...